A Phase II Window of Opportunity Trial of Ipilimumab and Nivolumab in Metastatic Recurrent HER2- Inflammatory Breast Cancer (IBC) The Win Trial
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Advanced breast cancer; Carcinoma
- Focus Therapeutic Use
- 01 May 2019 Status changed from active, no longer recruiting to discontinued.
- 18 Feb 2019 Planned number of patients changed from 29 to 3.
- 18 Feb 2019 Planned End Date changed from 1 Sep 2020 to 1 Sep 2021.